Article
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
29 Dec 2022
Abstract excerpt
Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly, a subset of MMRp CRCs contains variable fractions of MMRd cells, but it is unknown how their presence impacts immune surveillance. We asked whether modulation of the MMRd fraction...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
